1. Home
  2. AGO vs ACAD Comparison

AGO vs ACAD Comparison

Compare AGO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assured Guaranty Ltd.

AGO

Assured Guaranty Ltd.

HOLD

Current Price

$85.36

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$24.84

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGO
ACAD
Founded
2003
1993
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.3B
IPO Year
2003
2000

Fundamental Metrics

Financial Performance
Metric
AGO
ACAD
Price
$85.36
$24.84
Analyst Decision
Buy
Buy
Analyst Count
3
22
Target Price
$101.67
$30.55
AVG Volume (30 Days)
300.5K
1.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
1.67%
N/A
EPS Growth
49.34
69.12
EPS
1.91
0.02
Revenue
$1,110,000,000.00
$726,437,000.00
Revenue This Year
$3.06
$18.80
Revenue Next Year
N/A
$11.70
P/E Ratio
$44.08
$1,241.50
Revenue Growth
27.29
40.45
52 Week Low
$72.76
$19.69
52 Week High
$92.40
$28.35

Technical Indicators

Market Signals
Indicator
AGO
ACAD
Relative Strength Index (RSI) 66.43 51.72
Support Level $85.41 $20.56
Resistance Level $85.82 $25.36
Average True Range (ATR) 1.56 0.76
MACD 0.05 -0.26
Stochastic Oscillator 86.40 23.84

Price Performance

Historical Comparison
AGO
ACAD

About AGO Assured Guaranty Ltd.

Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: